Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

April 30, 2009

Study Completion Date

August 31, 2011

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

clofarabine

Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.

DRUG

Ara-C

Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.

Trial Locations (3)

35233

University of Alabama at Birmingham, Birmingham

44195

The Cleveland Clinic Foundation, Cleveland

68198

The University of Nebraska, Omaha

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT00081822 - Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter